JP2008001718A5 - - Google Patents

Download PDF

Info

Publication number
JP2008001718A5
JP2008001718A5 JP2007226723A JP2007226723A JP2008001718A5 JP 2008001718 A5 JP2008001718 A5 JP 2008001718A5 JP 2007226723 A JP2007226723 A JP 2007226723A JP 2007226723 A JP2007226723 A JP 2007226723A JP 2008001718 A5 JP2008001718 A5 JP 2008001718A5
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
heterocyclyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007226723A
Other languages
English (en)
Japanese (ja)
Other versions
JP4268651B2 (ja
JP2008001718A (ja
Filing date
Publication date
Priority claimed from GBGB0305681.9A external-priority patent/GB0305681D0/en
Application filed filed Critical
Publication of JP2008001718A publication Critical patent/JP2008001718A/ja
Publication of JP2008001718A5 publication Critical patent/JP2008001718A5/ja
Application granted granted Critical
Publication of JP4268651B2 publication Critical patent/JP4268651B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007226723A 2003-03-12 2007-08-31 フタラジノン誘導体 Expired - Lifetime JP4268651B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0305681.9A GB0305681D0 (en) 2003-03-12 2003-03-12 Phthalazinone derivatives
US45499503P 2003-03-14 2003-03-14
US49339903P 2003-08-06 2003-08-06
US52624403P 2003-12-01 2003-12-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006505955A Division JP4027406B2 (ja) 2003-03-12 2004-03-12 フタラジノン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008260806A Division JP2009079056A (ja) 2003-03-12 2008-10-07 フタラジノン誘導体

Publications (3)

Publication Number Publication Date
JP2008001718A JP2008001718A (ja) 2008-01-10
JP2008001718A5 true JP2008001718A5 (enExample) 2008-02-21
JP4268651B2 JP4268651B2 (ja) 2009-05-27

Family

ID=32996122

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006505955A Expired - Lifetime JP4027406B2 (ja) 2003-03-12 2004-03-12 フタラジノン誘導体
JP2007226723A Expired - Lifetime JP4268651B2 (ja) 2003-03-12 2007-08-31 フタラジノン誘導体
JP2008260806A Pending JP2009079056A (ja) 2003-03-12 2008-10-07 フタラジノン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006505955A Expired - Lifetime JP4027406B2 (ja) 2003-03-12 2004-03-12 フタラジノン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008260806A Pending JP2009079056A (ja) 2003-03-12 2008-10-07 フタラジノン誘導体

Country Status (21)

Country Link
EP (1) EP1633724B1 (enExample)
JP (3) JP4027406B2 (enExample)
KR (1) KR101146806B1 (enExample)
AU (1) AU2004220321B2 (enExample)
BR (1) BRPI0408284B8 (enExample)
CA (1) CA2517629C (enExample)
CO (1) CO5650256A2 (enExample)
CY (1) CY1111597T1 (enExample)
EA (1) EA009469B1 (enExample)
EC (1) ECSP056094A (enExample)
GB (1) GB2415430B (enExample)
HR (1) HRP20050895B1 (enExample)
IS (1) IS2813B (enExample)
LT (1) LTC1633724I2 (enExample)
MA (1) MA27758A1 (enExample)
MX (1) MXPA05009661A (enExample)
NO (2) NO331807B1 (enExample)
NZ (1) NZ542680A (enExample)
PL (1) PL1633724T3 (enExample)
TN (1) TNSN05212A1 (enExample)
WO (1) WO2004080976A1 (enExample)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
KR101146806B1 (ko) * 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
EP1651620B1 (en) 2003-07-30 2011-11-09 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US20070104709A1 (en) 2003-08-06 2007-05-10 Xiaodong Li T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
DK2305221T3 (en) * 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
WO2006021801A1 (en) * 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
EP1645556A1 (en) * 2004-10-07 2006-04-12 Boehringer Ingelheim International GmbH Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
SG159528A1 (en) * 2005-02-04 2010-03-30 Senomyx Inc Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
WO2007035010A2 (en) 2005-09-23 2007-03-29 Equispharm Co., Ltd 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2032140A1 (en) * 2006-05-31 2009-03-11 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
WO2007144637A1 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage
AU2013201880B2 (en) * 2006-10-17 2015-06-25 Kudos Pharmaceuticals Limited Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
PH12012501544A1 (en) 2006-12-28 2024-06-03 Abbvie Inc Inhibitors of poly (adp-ribose) polymerase
WO2008146035A1 (en) * 2007-05-25 2008-12-04 Astrazeneca Ab Combination of chk and parp inhibitors for the treatment of cancers
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
GB0716532D0 (en) * 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102083314B (zh) 2007-10-03 2014-04-30 卫材股份有限公司 Parp抑制剂化合物、组合物以及使用方法
RU2487868C2 (ru) * 2007-10-17 2013-07-20 Кудос Фармасеутикалс Лимитед 4-[3-(4-циклопропанкарбонил-пиперазин-1-карбонил)-4-фтор-бензил]-2н-фталазин-1-он
KR101641596B1 (ko) 2007-11-15 2016-07-21 엠에스디 이탈리아 에스.알.엘. Ｐａｒｐ 억제제로서의 피리다지논 유도체
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
CA2708364A1 (en) 2007-12-11 2009-06-18 Efrat Ben-Zeev Carboxamide compounds and their use as chemokine receptor agonists
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
WO2010017055A2 (en) 2008-08-06 2010-02-11 Lead Therapeutics, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
NZ592719A (en) * 2008-10-07 2012-09-28 Astrazeneca Uk Ltd PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
US20110015393A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (es) * 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
AR083502A1 (es) * 2010-10-21 2013-02-27 Biomarin Pharm Inc Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina
ES2590682T3 (es) * 2010-12-02 2016-11-23 Shanghai De Novo Pharmatech Co Ltd. Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos
US9090568B2 (en) * 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
CA2833914A1 (en) * 2011-05-10 2012-11-15 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
CN103827314A (zh) 2011-05-18 2014-05-28 国家科学研究中心 用于诊断癌侵袭性和遗传不稳定性的标记
ES2871052T3 (es) * 2011-05-31 2021-10-28 Rakovina Therapeutics Inc Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
SG10201605814QA (en) 2011-07-22 2016-09-29 Pacylex Pharmaceuticals Inc Synthetic lethality and the treatment of cancer
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
EP2800821B1 (en) 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of lung cancer aggressiveness
CN102964354B (zh) * 2012-11-16 2014-08-13 江苏先声药业有限公司 一类噻吩并咪唑衍生物及其应用
MA38080A1 (fr) 2012-12-31 2018-02-28 Cadila Healthcare Ltd Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
MX359656B (es) * 2013-07-31 2018-10-05 Merck Patent Gmbh Derivados de oxoquinazolinil-butanamida.
WO2015018475A1 (en) * 2013-08-07 2015-02-12 Merck Patent Gmbh Piperidine urea derivatives
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN105985294B (zh) * 2015-02-11 2020-12-25 四川科伦药物研究院有限公司 一种奥拉帕尼的制备方法
EP3280708B1 (en) 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
US10857140B2 (en) * 2015-05-06 2020-12-08 The Regents Of The University Of California K-Ras modulators
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
DK3325662T3 (da) 2015-07-17 2023-11-27 Pacylex Pharmaceuticals Inc Epigenetisk inaktivering af nmt2
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
CN106554316B (zh) * 2015-09-28 2019-03-08 上海医药集团股份有限公司 一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
KR20180113976A (ko) 2015-11-20 2018-10-17 센화 바이오사이언시즈 인코포레이티드 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
CZ201682A3 (cs) 2016-02-15 2017-08-23 Zentiva, K.S. Solvatované krystalické formy olaparibu, jejich příprava a použití
WO2017191562A1 (en) * 2016-05-04 2017-11-09 Alembic Pharmaceuticals Limited Process for the preparation of olaparib and polymorphs thereof
US11072600B2 (en) 2016-06-24 2021-07-27 The Regents Of The University Of California Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
CZ2016391A3 (cs) 2016-06-29 2018-01-10 Zentiva, K.S. Farmaceutická formulace olaparibu
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018038680A1 (en) * 2016-08-24 2018-03-01 Scinopharm Taiwan, Ltd. Processes for preparing olaparib
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN107955001A (zh) * 2016-10-14 2018-04-24 上海汇伦生命科技有限公司 抗肿瘤杂环并咪唑类化合物的药用盐
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018255413A1 (en) 2017-04-20 2019-12-05 Leidos Biomedical Research, Inc. K-Ras modulators
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
CA3031777A1 (en) 2018-01-31 2019-07-31 Apotex Inc. Crystalline form of olaparib
WO2019168688A2 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
JP2021516229A (ja) * 2018-02-28 2021-07-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤
JP7534218B2 (ja) 2018-03-13 2024-08-14 ヴァレリオ・セラピューティクス がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
GB201804924D0 (en) * 2018-03-27 2018-05-09 Univ Oxford Innovation Ltd Radiolabelled compound
CN110357889B (zh) * 2018-04-09 2022-03-15 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
WO2019222272A1 (en) * 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN108558773A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种奥拉帕尼药物中间体的制备方法
EP3829580A1 (en) 2018-08-01 2021-06-09 Araxes Pharma LLC Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020232119A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114144413B (zh) 2019-07-19 2024-08-16 阿斯利康(瑞典)有限公司 Parp1抑制剂
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4087563A4 (en) * 2020-01-07 2024-03-27 Shanghai Huayu Biotechnology Co., Ltd. CANCER COMBINATION THERAPY USING A CHK INHIBITOR
JP2023509191A (ja) 2020-01-09 2023-03-07 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4112049A4 (en) * 2020-02-24 2024-07-24 Fukang (Shanghai) Health Technology Co., Ltd. ANTI-CORONAVIRUS APPLICATION OF POLY ADP-RIBOSE POLYMERASE INHIBITOR
AU2020444056A1 (en) 2020-04-21 2022-11-17 Idience Co., Ltd. Crystalline forms of phthalazinone compound
EP4139298A4 (en) 2020-04-21 2024-05-22 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
AU2021262569A1 (en) 2020-04-28 2022-11-24 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors
CN111592522B (zh) * 2020-06-17 2022-09-09 郑州大学 一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
WO2022058785A1 (en) 2020-09-16 2022-03-24 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use
TW202222350A (zh) 2020-10-09 2022-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及parp1選擇性抑制劑之組合
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN112500379B (zh) * 2020-12-23 2024-01-23 南京方生和医药科技有限公司 一种奥拉帕利中间体及奥拉帕利的制备方法
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113024516B (zh) * 2021-03-29 2022-05-17 中国药科大学 双靶点parp/ezh2抑制剂、制备方法及用途
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
WO2022245131A1 (ko) 2021-05-18 2022-11-24 온코닉 테라퓨틱스 주식회사 Parp 저해제 저항성 암 치료제
WO2022253800A1 (en) 2021-06-02 2022-12-08 Astrazeneca Ab Methods of treating breast cancer
EP4384501A4 (en) 2021-08-09 2025-01-22 Glenmark Life Sciences Limited Process for the preparation of olaparib, and crystalline form thereof
KR102645122B1 (ko) 2021-08-25 2024-03-07 주식회사 보령 올라파립의 제조방법
CN120309514A (zh) * 2021-09-15 2025-07-15 上海博邦医药科技有限公司 一种奥拉帕尼中间体的制备方法
US12049452B2 (en) 2021-11-10 2024-07-30 Nuformix Technologies Limited Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CA3242082A1 (en) 2021-12-21 2023-06-29 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
KR102776660B1 (ko) * 2022-01-25 2025-03-04 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도
KR20240148418A (ko) 2022-02-15 2024-10-11 아스트라제네카 아베 전립선암을 치료하는 방법
WO2024199668A1 (en) 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regiment of azd5305
TW202515604A (zh) 2023-05-31 2025-04-16 瑞典商阿斯特捷利康公司 用於治療卵巢癌之方法、組成物和組合
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
CN119488588A (zh) 2023-08-17 2025-02-21 阿斯利康(瑞典)有限公司 用于治疗子宫内膜癌的方法、组合物和组合
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
WO2025153668A1 (en) 2024-01-19 2025-07-24 Astrazeneca Ab Pharmaceutical compositions comprising azd5305

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100804564B1 (ko) * 2000-10-30 2008-02-20 쿠도스 파마슈티칼스 리미티드 프탈라지논 유도체
EP1397350B1 (en) * 2001-05-08 2007-02-28 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
KR101146806B1 (ko) * 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체

Similar Documents

Publication Publication Date Title
JP2008001718A5 (enExample)
JP2006519827A5 (enExample)
JP2008510783A5 (enExample)
JP2011510056A5 (enExample)
TWI827646B (zh) Ptpn11抑制劑
KR102159442B1 (ko) 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용
JP2008535902A5 (enExample)
CA2517629A1 (en) Phthalazinone derivatives
CN113811333B (zh) 靶向抗癌核激素受体的化合物
JP2008535903A5 (enExample)
JP2008531537A5 (enExample)
JP2009541223A5 (enExample)
EA026514B1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
JP2004518723A5 (enExample)
JP2012507566A5 (enExample)
JP2012533623A (ja) Ｈｄａｃ阻害剤およびそれを用いる治療法
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
JP6272982B2 (ja) Ａｐｅ１媒介疾患を処置するためのキノン化合物
JP2016511237A (ja) 選択的ｈｄａｃ３阻害剤
US20130012709A1 (en) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
AU724909B2 (en) Use of aryl N-substituted carboxamides to kill tumors
CN109689060A (zh) 组合化学治疗
RU2010108008A (ru) Фталазиноновые производные
JP2018501261A5 (enExample)
JP6557253B2 (ja) 抗腫瘍化合物としてのシグマ−２受容体リガンド薬物結合体、その合成法及び使用